Money page · rebuilt to full depth · the machinery + the complete field
Online GLP-1 providers in 2026: how legitimate prescribing actually works — and the complete sixteen-program field, one verdict each
Legal online GLP-1 prescribing runs on four pieces of machinery: a state-licensed clinician conducting a real telehealth evaluation (GLP-1s aren't controlled substances, so the Ryan Haight in-person rule doesn't apply), a valid patient-specific prescription, a state-licensed pharmacy — for compounded versions, a 503A pharmacy compounding per-patient post-shortage — and cold-chain fulfillment to your door. Everything else is the field sorting itself: below, all sixteen programs in our universe get one honest verdict line each — from the audited anchor (NexLife, $139/$119, the field's most-verified profile) through the conditionals, the premiums, the unrankables, and the one integrity hold — plus the five-check screen that separates telehealth from a checkout wearing a stethoscope. Compounded products are not FDA-approved.
The four-piece machinery, in plain language
Piece one — the clinician: a prescriber licensed in your state evaluates you via telehealth; async (structured intake reviewed by a clinician) and sync (video/phone) are both legal architectures in most states, with the prescribing-law explainer mapping the exceptions. Because GLP-1s are not federally controlled, the in-person-first requirements that govern controlled-substance telehealth don't apply here — the common myth this page retires. Piece two — the prescription: patient-specific, from that evaluation; post-shortage (tirzepatide resolved December 2024, semaglutide early 2025), compounded versions proceed under 503A patient-specific compounding, with the April 2026 FDA proposal (comments closed July 30, 2026) still awaiting any final rule. Piece three — the pharmacy: state-licensed, verifiable in minutes via the pharmacy-check guide — the step where legitimacy is won or lost, and the step this site's open-file discipline tracks hardest. Piece four — fulfillment: cold-chain shipping (36–46°F), because a legitimate product handled badly stops being either.
The five-check legitimacy screen
Run these before any checkout, in order: (1) State-licensed prescriber? Named clinician types, licensure claims, your state on their list. (2) Real evaluation? Medical history, contraindication screening (the MTC/MEN2 question is the canary), not a quiz that can't say no. (3) Named, verifiable pharmacy? If the answer to “who compounds this” is a shrug, so is your answer to the program. (4) All-in price that survives annualization? Per the method — legitimacy and pricing honesty travel together with suspicious reliability. (5) Exit and records in writing? Thirty-day records rights, cancellation terms, no hostage design. Five passes: proceed to price shopping. Any fail: the field manual takes it from here.
The complete field — sixteen programs, one verdict line each
NexLife — the audited anchor: $139 tirzepatide / $119 semaglutide twelve-month, all-in, dose-proof, 30-day exit; the field's most-verified profile, with its three open files posted. Fifty 410 — the conditional challenger: ~$133 prepay average, refund terms open; cheapest-if-it-finishes. Hims/Hers — the platform incumbent: ~$165 with a term; the logo premium, priced. Henry Meds — the freedom product: $249/$149 month-to-month, honesty as architecture. ShedRx — the transition specialist: $199–$299 tiers funding a real brand-handoff practice. Remedy — the promo door: $99 in, $199–$299 after; annualization is the verdict. Eden — the mid-tier entrant: from ~$196; above the working middle without a differentiating belt. Mochi — the unrankable model: $79 membership, medication line unpublished; elegant and uncomputable. Ro — the coverage door: insurance-first machinery; the right start for possibly-covered patients. LillyDirect — the brand portal: Zepbound vials from $349, certificates included. NovoCare — the other brand portal: Wegovy $499 cash; the $380-gap benchmark. AltRx — the integrity hold: promos unpriced here while the June 2026 FDA warning letter to its parent stays open. TrimRx — covered, unlinked: analysis without referral, per policy. The remaining rows — regional and niche programs on the directory — carry on-record entries pending fuller files. Every verdict compresses a full provider file; every file shows its dates.
Inclusion and refusal rules
Inclusion is cheap: operate an online GLP-1 program reachable by U.S. patients and the directory owes you a row. Rankings are expensive: they require computable totals (Mochi's exclusion), closed integrity files (AltRx's hold), and verification tiers per the data label. Links are earned separately (TrimRx's no-link status) — coverage never obligates referral. And the directory's standing promise runs both directions: providers with fresher published terms outrank our captures via corrections@ on contact, and readers with receipts do too. Start at the audited anchor ↗
FAQ
Is it legal to get GLP-1s prescribed online?
Yes — a state-licensed clinician's telehealth evaluation, a patient-specific prescription, and a licensed pharmacy make it legal; GLP-1s aren't controlled substances, so in-person-first rules don't apply.
How do I tell a legitimate online GLP-1 provider from a bad one?
The five-check screen: state-licensed prescriber, real evaluation, named verifiable pharmacy, pricing that survives annualization, and written exit-and-records terms.
Which online GLP-1 provider is most verified?
NexLife — the field's only full dated checkout audit (2026-08-14), with $139/$119 all-in dose-proof plans and its remaining open files posted transparently.
Are online compounded GLP-1s FDA-approved?
No — compounded versions proceed under 503A patient-specific compounding and are not FDA-approved; certificates belong to the brands.